BILTHOVEN, Netherlands--(BUSINESS WIRE)--Avania, the leading, global medical technology contract research organization (CRO) and advisory services partner, today announced its acquisition of Anagram. Headquartered in Barcelona, Spain, Anagram is one of the leading MedTech CROs in the Iberian Peninsula, providing MedTech solutions to its customers in Spain, the wider European market, and beyond..

荷兰比尔托芬——（商业新闻短讯）——领先的全球医疗技术合同研究组织（CRO）和咨询服务合作伙伴Avania今天宣布收购Anagram。Anagram总部位于西班牙巴塞罗那，是伊比利亚半岛领先的MedTech CRO之一，为其在西班牙、更广泛的欧洲市场及其他地区的客户提供MedTech解决方案。

Founded in 1998, Anagram delivers a full service CRO model to their customers including diagnostic imaging core lab (centralized quality control and central assessment of images in clinical trials) services. It is focused on cardiology, oncology, and neurology therapeutic areas. They conduct studies in the U.S., U.K., Spain, Netherlands, France, Germany, and more..

Anagram成立于1998年，为客户提供全方位的CRO模型服务，包括诊断成像核心实验室（临床试验中图像的集中质量控制和中央评估）服务。它专注于心脏病学，肿瘤学和神经病学治疗领域。他们在美国、英国、西班牙、荷兰、法国、德国等地进行研究。

Anagram is a perfect fit for Avania, enabling the company to increase CRO business in Spain and providing greater access to a growing MedTech country. The addition will support cross-sell opportunity by adding scale and will eliminate reliance on current outsourcing partners. Avania customers will benefit from an expanded geographic footprint and an enhanced roster of subject matter experts concentrated on areas of key therapeutic expertise..

Anagram非常适合Avania，使该公司能够增加西班牙的CRO业务，并为不断增长的医疗技术国家提供更多机会。这一增加将通过增加规模来支持交叉销售机会，并将消除对当前外包合作伙伴的依赖。Avania的客户将受益于地理范围的扩大和专注于关键治疗专业领域的主题专家名单的增强。

“The addition of Anagram furthers our vision of becoming a trusted global partner for the MedTech community, advancing innovations from bench to bedside and improving patient outcomes globally,” said Jason Monteleone, president and CEO of Avania. “It will provide us with a significant footprint in Spain and Southern Europe and further strengthen our cardiovascular and neurology franchises while expanding our oncology capabilities.”.

Avania总裁兼首席执行官杰森·蒙特利昂（JasonMonteleone）表示：“Anagram的加入进一步推动了我们成为医学技术界值得信赖的全球合作伙伴的愿景，推动了从实验室到床边的创新，并在全球范围内改善了患者的预后。”。“它将为我们在西班牙和南欧提供重要的足迹，并进一步加强我们的心血管和神经病学特许经营权，同时扩大我们的肿瘤学能力。”

About Avania

关于Avania

Avania is the leading global MedTech clinical research organization and advisory partner with a focus on medical devices, diagnostics/IVDs, and digital health. Core offerings include full service clinical research outsourcing, market access, reimbursement, regulatory, and product development advisory services.

Avania是全球领先的医学技术临床研究组织和咨询合作伙伴，专注于医疗设备、诊断/IVD和数字健康。核心服务包括全方位的临床研究外包、市场准入、报销、监管和产品开发咨询服务。

Avania’s vision is to be your trusted global partner in the evolution of your medical technology from innovation to commercialization to improving patient health and well-being. When you need to advance your medical technology, It Takes Avania..

Avania的愿景是成为您值得信赖的全球合作伙伴，推动您的医疗技术从创新到商业化，再到改善患者的健康和福祉。当你需要提高你的医疗技术时，需要Avania。

About Anagram

关于字谜

Anagram is a Clinical Research Organization (CRO) based in Spain providing high quality services in clinical development and post-authorization trials for drugs and medical devices. Services include image central reading (core lab), analysis, and reporting by highly experienced professionals. Anagram has specialized expertise in cardiology, neurology, and oncology..

Anagram是一家位于西班牙的临床研究组织（CRO），为药物和医疗器械的临床开发和授权后试验提供高质量的服务。服务包括由经验丰富的专业人员进行图像中心阅读（核心实验室）、分析和报告。Anagram在心脏病学、神经病学和肿瘤学方面拥有专业知识。